Functional improvement of dystrophic muscle by myostatin blockade. - Wikidata - awgldk - TriplyDB

Functional improvement of dystrophic muscle by myostatin blockade.

Functional improvement of dystrophic muscle by myostatin blockade.

http://www.wikidata.org/entity/Q44234792

about

Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2 Regulation of muscle growth by multiple ligands signaling through activin type II receptors.Follistatin gene delivery enhances muscle growth and strength in nonhuman primates Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting Myostatin regulates cardiomyocyte growth through modulation of Akt signaling Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.Myostatin negatively regulates satellite cell activation and self-renewal Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials The quasi-parallel lives of satellite cells and atrophying muscle Advancements in stem cells treatment of skeletal muscle wasting Pharmacology of manipulating lean body mass Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures.Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease Emerging drugs for sarcopenia: age-related muscle wasting A mouse model for dominant collagen VI disorders: heterozygous deletion of Col6a3 Exon 16 Impaired membrane resealing and autoimmune myositis in synaptotagmin VII-deficient mice Genetic analysis of the role of proteolysis in the activation of latent myostatin Mechanisms limiting body growth in mammals Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.Structural basis for potency differences between GDF8 and GDF11.Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm.Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity.Redundancy of myostatin and growth/differentiation factor 11 function Functional substitution by TAT-utrophin in dystrophin-deficient mice.Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology.Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model.Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor.

P2860

Q21090110-BF04E61C-7E18-4E3E-B0F8-3CF878968C2C Q21245430-3C0225C8-CA2B-43A7-B1B8-D64DF3070ADB Q24296422-829A2D66-18E0-46C3-A1D7-8415F2C155DE Q24297583-F7B2CC4A-4381-478F-8AF6-84B3276B42E6 Q24538732-4D953760-63F5-48CF-B0D0-E99D9CB35CF2 Q24598350-F6B6E39E-2E51-40ED-B96F-1C904B3959E1 Q24609841-B6412531-3CBB-446C-96C2-6E898C73D8E5 Q24614013-B344BC91-7F23-4FFF-95AB-00A9B4B6947E Q24646933-EDBB702F-7CE9-4967-B241-5E2F63F36597 Q24647245-53E19298-02ED-447A-9475-01F0E0FD46E7 Q24675245-D1E65387-7160-43CC-88BA-AB06B509FC02 Q26741409-4F768556-A407-4119-93ED-1B99BE93941F Q26800207-E28FAD4C-39BE-4C74-B632-31A073E9EEE9 Q26822437-38DA5D7E-5368-47FD-8B10-779D9AA76F01 Q26824503-038B5B03-4E81-4EF8-8A65-7B359D43E28F Q26849430-75597C52-5F2B-4448-A2F7-74A37EC7B559 Q27308903-03946ED1-F6BC-4411-A7C4-1DD4EAFA6B8C Q27321253-97605A0A-1F66-4F8B-AF2B-DCE3A1A63A4E Q27438151-6377A24A-A40B-44A6-96DC-06EA994AE70A Q28069464-B0495CB6-06EC-43F8-A13D-382D45D5DA33 Q28072184-DE9A8B45-C63A-4E56-9BA1-F3744ED2AE97 Q28295716-FC006256-F8CF-4AF4-BF5A-574BECDEF3C4 Q28505521-7F1A9CE6-411D-4CF8-AC4E-6176612FD076 Q28511824-919866A7-FAE5-4897-A675-C4686FE54A64 Q28592774-0E00C4C3-A1B3-4EC1-83AB-A9B38B9615A2 Q28728958-A996DBC6-52FB-43BB-AF06-BAE4271FFE72 Q28749276-8E8C0540-223C-489E-8AF9-3CAA49873CD2 Q28751044-600A9F91-3069-43E8-B08C-3C72B0271043 Q30478055-1AC93B43-4671-4F2A-9B4A-709897A4ADAA Q30841381-7E3F08B7-B1E5-47A7-8292-F42E8CE7715E Q31813087-48B21668-8FDB-4E84-94B1-178081A87C5B Q33369840-9FAE6E75-CE5A-47DB-9F92-CF7F9EDA7C97 Q33398588-3378EAC1-F83E-463D-9FC2-67C38D14EDE2 Q33419373-A24C6CBC-6C9B-4A58-8BB0-6CA66ADF556E Q33419706-E6B2F878-35CA-43F0-9DA0-DFD7A344684B Q33455443-4EB8ADAA-5EA9-4279-A76D-D907A2A9DAEB Q33531816-CC57EB7D-5437-42CB-893B-94981CBA4327 Q33556205-7C971465-B7D3-4859-B775-B0F943E57490 Q33564220-59BD26D6-3F69-4A63-B3D5-F71E5D8DAC82 Q33570741-E7BD3A3F-54EE-471A-8EC9-970E32F6C877

P2860

Functional improvement of dystrophic muscle by myostatin blockade.

http://www.wikidata.org/entity/Q44234792

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Functional improvement of dystrophic muscle by myostatin blockade.

@en

Functional improvement of dystrophic muscle by myostatin blockade.

@nl

type

label

Functional improvement of dystrophic muscle by myostatin blockade.

@en

Functional improvement of dystrophic muscle by myostatin blockade.

@nl

prefLabel

Functional improvement of dystrophic muscle by myostatin blockade.

@en

Functional improvement of dystrophic muscle by myostatin blockade.

@nl

P1433

Q44234792-4EC3CCA5-10FA-44FC-8DD4-93A03E67967E

P1476

Q44234792-0BC89F36-01A0-4363-81DE-A4CBAC034670

P2093

Q44234792-235CC15D-2245-47DD-AAF4-BFD70DBD3857

Q44234792-3D70334C-9152-4D5E-9056-FDAC050420F4

Q44234792-4F3A372E-73F2-480D-9FD8-F739F70FFF12

Q44234792-5BE5AD96-F799-4363-BD93-D865A36410BF

Q44234792-D8908F20-5B7B-47BA-8615-293081355578

Q44234792-DEE549E4-0061-4F95-8D75-ADCD7BC91F2A

P2888

Q44234792-E146E466-F858-4B78-A751-560349FD9A09

P304

Q44234792-0E259355-5DBE-42DC-8AF7-580305C4BD08

P31

Q44234792-A7A77B34-66FE-4A5E-ABFB-A047A0D26DC7

P356

Q44234792-19279BD8-B36E-4284-8938-2A6544A00354

P407

Q44234792-82DB2526-FEB1-4718-9C70-0F93395635CE

P433

Q44234792-D7236C06-CD0D-4CB0-8167-0078F5568C44

P478

Q44234792-984A5185-DD23-4E74-B342-7FF456165EE3

P50

Q44234792-B6E3598D-FBB8-4C03-A724-6079B681CC4F

P577

Q44234792-9BA4A273-8EE4-4670-BB20-891751CD3869

P6179

Q44234792-DC05C8ED-420D-4FF7-9B45-639F2C855368

P698

Q44234792-04776492-9743-4C26-804D-84E87FC8DA36

P356

P1433

P1476

Functional improvement of dystrophic muscle by myostatin blockade

@en

P2093

Elisabeth R Barton

http://www.w3.org/2001/XMLSchema#string

Linda D Morris

http://www.w3.org/2001/XMLSchema#string

Lisa-Anne Whittemore

http://www.w3.org/2001/XMLSchema#string

Rexford S Ahima

http://www.w3.org/2001/XMLSchema#string

Sasha Bogdanovich

http://www.w3.org/2001/XMLSchema#string

Tejvir S Khurana

http://www.w3.org/2001/XMLSchema#string

P2888

P304

418-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE01154

http://www.w3.org/2001/XMLSchema#string

P407

P433

6914

http://www.w3.org/2001/XMLSchema#string

P478

420

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021809955

http://www.w3.org/2001/XMLSchema#string

P698

12459784

http://www.w3.org/2001/XMLSchema#string